Christophe Massard

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou et al. · The Lancet Oncology · 2018 · 1.2K citations

Medicine, Immunology, Oncology +17

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari et al. · Clinical Cancer Research · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +17

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 776 citations

Medicine, Molecular Biology, Oncology +17

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

David F. McDermott, Jeffrey A. Sosman, Mario Sznol et al. · Journal of Clinical Oncology · 2016 · 558 citations

Medicine, Oncology, Pharmacology +17

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

Céline Lefèbvre, Thomas Bachelot, Thomas Filleron et al. · PLoS Medicine · 2016 · 405 citations · Full text

Medicine, Genetics, Oncology +17